Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR070803 in advanced esophageal cancer
CTR20221384Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2022
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of CPO-120 in esophageal cancer, sponsored by Hengrui Therapeutics. Started Jun 2022; status: completed.
02
Drugs
CPO-120
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on CTR20221384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221384.